Heska (NASDAQ:HSKA) Given Media Impact Rating of 0.10

News stories about Heska (NASDAQ:HSKA) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Heska earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 46.6152065076622 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:

How to Become a New Pot Stock Millionaire

Several analysts have issued reports on the stock. BidaskClub raised shares of Heska from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. Zacks Investment Research downgraded shares of Heska from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. ValuEngine downgraded shares of Heska from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Sidoti raised shares of Heska from a “neutral” rating to a “buy” rating and set a $94.00 price objective on the stock in a research note on Monday, February 5th. Finally, B. Riley set a $93.00 price target on shares of Heska and gave the stock a “hold” rating in a research report on Monday, February 26th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $104.08.

Shares of HSKA stock traded down $1.18 on Thursday, hitting $80.36. The stock had a trading volume of 8,329 shares, compared to its average volume of 96,701. The company has a market capitalization of $590.19, a PE ratio of 38.20, a price-to-earnings-growth ratio of 2.20 and a beta of 0.65. Heska has a 52-week low of $56.59 and a 52-week high of $115.00.

Heska (NASDAQ:HSKA) last announced its earnings results on Wednesday, February 28th. The medical research company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.07. Heska had a net margin of 7.53% and a return on equity of 16.23%. The business had revenue of $36.04 million during the quarter, compared to the consensus estimate of $40.56 million. During the same period in the prior year, the firm earned $0.46 earnings per share. The business’s quarterly revenue was down 8.8% compared to the same quarter last year. research analysts forecast that Heska will post 1.95 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://ledgergazette.com/2018/04/19/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-heska-hska-share-price.html.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.

Insider Buying and Selling by Quarter for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply